Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931150 · ClinicalTrials.gov registry record · Phase 3
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT01931150: Completed Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01931150 is a Phase 3 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01931150, a Phase 3 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin. One topical agent is the dapsone gel and the other is a skin moisturizer. Dapsone gel is an FDA approved medication that you apply to the face. It is commonly used to treat acne. Skin moisturizers are recommended to patients who receive Cetuximab treatment. In addition to these topical agents they will be given a pill to take once a day. This pill has already been shown to help fight rashes from Cetuximab.
Interventions
- OTHER Moisturizer
- DRUG Topical Dapsone 5% Gel
- DRUG oral antibiotics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931150
The ClinicalTrials.gov registry entry for NCT01931150 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moisturizer is the first listed.
NCT01931150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931150 about?
NCT01931150 is a clinical study titled "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT". The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin. One topical agent is the dapsone gel and the other is a skin moisturizer. Dapsone gel is an FDA approved medicatio...
What is the current status of trial NCT01931150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2013-08. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01931150?
The interventions under investigation include: Moisturizer (OTHER), Topical Dapsone 5% Gel (DRUG), oral antibiotics (DRUG).
Who is sponsoring clinical trial NCT01931150?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.